3-keto-desogestrel (etonogestrel)

Subscribe to Selected New Research on 3-keto-desogestrel

57 relevant articles (4 outcomes, 15 trials/studies) found for this Drug

Description: metabolite of DESOGESTREL; structure given in first source; Implanon: implant containing etonogestrel (3-keto-desogestrel)

Also Known As:

etonogestrel; Implanon; 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; 3-ketodesogestrel; 3-oxo desogestrel; 3-oxodesogestrel; Nourypharma brand of 3-keto-desogestrel; Organon brand of 3-keto-desogestrel; 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)-

Relationship Network

Drug Context: Research Results

Polycyclic Compounds: 58

3-keto-desogestrel: 57

Experts

1.	Fraser, Ian S: 2 articles (06/2008 - 06/2007)
2.	Korver, Tjeerd: 1 article (06/2008)
3.	Mansour, Diana: 1 article (06/2008)
4.	Marintcheva-Petrova, Maya: 1 article (06/2008)
5.	Hughes-Gage, Hayley: 1 article (04/2008)
6.	Cogswell, Charlotte: 1 article (04/2008)
7.	Cook, Louise: 1 article (04/2008)
8.	Palmer, John: 1 article (06/2007)
9.	Al-Jefout, Moamar: 1 article (06/2007)
10.	Gillespie, Morven D: 1 article (04/2007)

Related Diseases

1.	Hemorrhage 01/01/2006 - "The aim of this study was to compare three treatments with placebo on the duration and recurrence of frequent and/or prolonged bleeding in Implanon users" 03/01/1999 - "In conclusion, this pilot efficacy study indicates that Implanon provides excellent contraceptive reliability and an acceptable bleeding pattern" 03/01/1999 - "In this 4-year open-label, noncomparative, single-center pilot efficacy study, the contraceptive efficacy, safety, bleeding pattern and acceptability of Implanon was studied in 200 sexually active women of proven fertility in Indonesia" 12/01/1998 - "An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon." 06/01/2008 - "CONCLUSION: Implanon use is associated with an unpredictable bleeding pattern, which includes amenorrhoea and infrequent, frequent, and/or prolonged bleeding" Order ALL the reference details at left...
2.	Endometriosis (Adenomyosis) 10/01/2005 - "OBJECTIVE: To evaluate the efficacy of Implanon on treatment of symptomatic endometriosis DESIGN: An open clinical study without control group SETTING: Family Planning Clinic and out patient department, King Chulalongkorn Memorial Hospital, Bangkok, Thailand" 01/01/2005 - "METHODS: Our study was not planned research but a series of case studies of women with severe symptoms of endometriosis treated in an innovative way with a new long-acting progestogen contraceptive system (etonogestrel subdermal implant) which could reasonably have been expected to have a favourable effect on their disease and its symptoms" 10/01/2005 - "CONCLUSION: Implanon, a sub-dermalprogestin implant is an effective hormonal alternative for treatment of symptomatic endometriosis" 10/01/2005 - "The effects of implanon in the symptomatic treatment of endometriosis." 01/01/2005 - "CONCLUSION: Etonogestrel subdermal implants are an additional treatment option in women with symptoms related to pelvic endometriosis." Order ALL the reference details at left...
3.	Acne Vulgaris 12/01/1998 - "The adverse events that most often caused discontinuation of Implanon were weight gain and acne" 12/01/1998 - "The development or aggravation of acne was a frequent adverse event (in 18.5% of Implanon and 22.3% of Norplant users in the comparative studies) but individual studies indicated that there were also many subjects whose acne improved during implant use" 10/25/2003 - "Three women developed severe acne vulgaris within several weeks to a few months after either insertion of a levonorgestrel IUD (two women, 27 and 33 years of age) or subcutaneous implantation of an etonogestrel implant (26-year-old woman)" Order ALL the reference details at left...
4.	Dysmenorrhea (Menstrual Pain) 12/01/1998 - "Dysmenorrhea clearly improved during use of both Implanon and Norplant" 12/01/2007 - "Implanon has been shown to be safe to use during lactation, may improve dysmenorrhea, and does not significantly affect bone mineral density, lipid profile, or liver enzymes." 01/01/1995 - "Contraception for women comprises the following: 1) agents that prevent ovulation; prolonged breast feeding (98% safe contraception within the first 6 months); oral contraceptives containing estrogens and gestagens (60-80 million women use them worldwide; in 1968 the 50 g estrogen containing pill, in 1972 the micropill with 30 g of ethinyl estradiol [EE], and in 1992 the ultra-low-dose pill with 20 g of EE were introduced); and future developments (third generation progestagens, antigestagens, nonsteroidal natural substances, melatonin, the combination of gonadotropin-releasing hormone analogs and natural estrogens); 2) prevention of fertilization: mechanical methods (diaphragm, sterilization methods by laparoscopy or chemical means); chemical methods (spermicides such as nonoxynol); behavioral methods (temperature methods using refined measurement of the body temperature, cervical mucus resistance); hormonal methods (implants such as Norplant containing levonorgestrel [LNG], Implanon containing 3-ketodesogestrel, the vaginal ring [the WHO-ring and the Organon ring], the minipill with pure gestagen, one-month injection with Cyclofem), IUDs (copper-containing IUDs, LNG-containing IUDs with a Pearl Index of 0.2-0.5 and reduction of dysmenorrhea); and immunological contraception (ovum and spermatozoon antigens); 3) the prevention of implantation: hormonal methods (the morning-after pill with high-dose EE or the combination of estrogen and gestagen); insertion of an IUD up to the 6th day after coitus; immunological methods (human chorionic gonadotropin antibodies, antibodies against the zona pellucida glycoproteins, implantation inhibition through interaction with interleukin IL-1 receptor, and antibodies against specific proteins of the endometrium influencing implantation)" Order ALL the reference details at left...
5.	Metrorrhagia (Spotting) 07/01/1999 - "The median number of bleeding/spotting (B/S) days with Implanon decreased from 33.5 in the first period to 19.0-21.5 days in the last year" 12/01/1998 - "There were statistically significant lower mean values over RP 2-8 the range over RP 2-8 is presented) for Implanon, for the number of bleeding-spotting days (15.9-19.3 vs 19.4-21.6; p = 0.0169), the number of bleeding days (7.5-10.0 vs. 11.7-13.1; p < 0.001), and the number of bleeding-spotting episodes (2.2-2.7 vs. 3.1-3.3; p < 0.0001)" 12/01/2003 - "The aim of the present study was to investigate the effects of St John's wort extract on oral contraceptive therapy with respect to ovarian activity, breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel" 12/01/2003 - "The number of breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel were assessed under steady-state conditions" 07/01/2003 - "Per 90-day reference period, the average number of bleeding-spotting days with Implanon decreased from 33 day in the first period to 21 day in the last year, and Norplant decreased from 31 day to 20 day" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Levonorgestrel (Plan B)
2.	Mifepristone (RU 486)
3.	Doxycycline (Vibramycin)
4.	3-keto-desogestrel (etonogestrel)
5.	Ethinyl Estradiol (Estinyl)
6.	Gonadotropin-Releasing Hormone (GnRH)
7.	Leuprolide (Lupron)
8.	Insulin (Novolin)
9.	Estradiol (Estrace)
10.	Gestodene

Related Therapies and Procedures

1.	Intrauterine Devices (Intrauterine Device)
2.	Female Contraceptive Devices (Vaginal Ring)
3.	Contraception (Birth Control)
4.	Contraceptive Devices (Contraceptive Device)
5.	Immunologic Contraception (Immunocontraception)

Best Treatments:
Research Summary Report
on Hemorrhage

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2879 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>